Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Ibrutinib, a first-in-class once-daily oral Bruton tyrosine kinase inhibitor indicated for chronic lymphocytic leukemia (CLL), is continued until progressive disease or unacceptable toxicity. We conducted an integrated safety analysis of single-agent ibrutinib from randomized phase 3 studies PCYC-11...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Coutre, Steven E., Byrd, John C., Hillmen, Peter, Barrientos, Jacqueline C., Barr, Paul M., Devereux, Stephen, Robak, Tadeusz, Kipps, Thomas J., Schuh, Anna, Moreno, Carol, Furman, Richard R., Burger, Jan A., O’Dwyer, Michael, Ghia, Paolo, Valentino, Rudolph, Chang, Stephen, Dean, James P., James, Danelle F., O’Brien, Susan M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2019
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595265/
https://ncbi.nlm.nih.gov/pubmed/31196847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018028761
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia